SCHEMBL2947103

SCHEMBL2947103

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccsc2)c1Nc1ccc(F)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 11/20 0.40
ALDH1A1 P00352 5/20 0.36
HPGD P15428 3/20 0.36
ALOX15 P16050 2/20 0.36
HSD17B10 Q99714 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BRAF P15056 1/20 0.34
EIF2AK3 Q9NZJ5 1/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 1/20 0.34
MCL1 Q07820 1/20 0.34
CDC7 O00311 1/20 0.33
DBF4 Q9UBU7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953040 0.89 ALDH1A1 (0.42) DHODHALDH1A1HPGDALOX15HSD17B10
SCHEMBL2952191 0.89 CSF1R (0.40) DHODHALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL1267006 0.89 DHODH (0.44) DHODHALDH1A1HPGDALOX15HSD17B10
SCHEMBL1266180 0.88 ALDH1A1 (0.45) DHODHALDH1A1HPGDALOX15HSD17B10
SCHEMBL1266272 0.86 DHODH (0.40) DHODHALDH1A1HPGDALOX15HSD17B10
SCHEMBL2958569 0.86 MAPT (0.43) DHODHALDH1A1HPGDLMNAKDM4E
SCHEMBL2949500 0.84 ALDH1A1 (0.38) ALDH1A1HPGDALOX15HSD17B10NPSR1
SCHEMBL1266134 0.80 DHODH (0.44) DHODHALDH1A1KDM4EMEN1KMT2A
SCHEMBL1266727 0.78 DHODH (0.34) DHODHALDH1A1NPSR1LMNAMEN1
SCHEMBL2952947 0.78 DHODH (0.43) DHODHALDH1A1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK DHODH 3134/4885ALDH1A1 1045/4885HPGD 3282/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 DHODH 3227/4885ALDH1A1 717/4885HPGD 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.